MARKET

AKRO

AKRO

Akero Therapeutics
NASDAQ
44.15
-0.71
-1.58%
After Hours: 43.30 -0.85 -1.93% 18:01 03/14 EDT
OPEN
44.86
PREV CLOSE
44.86
HIGH
45.58
LOW
43.98
VOLUME
599.31K
TURNOVER
--
52 WEEK HIGH
58.40
52 WEEK LOW
17.86
MARKET CAP
3.52B
P/E (TTM)
-11.7595
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at AKRO last week (0303-0307)?
Weekly Report · 4d ago
Evercore ISI Reaffirms Their Buy Rating on Akero Therapeutics (AKRO)
TipRanks · 03/07 07:48
Analysts Offer Insights on Healthcare Companies: Akero Therapeutics (AKRO), Immunovant (IMVT) and 4D Molecular Therapeutics (FDMT)
TipRanks · 03/03 12:50
Akero Therapeutics Is Maintained at Buy by HC Wainwright & Co.
Dow Jones · 03/03 12:28
Akero Therapeutics Price Target Raised to $75.00/Share From $72.00 by HC Wainwright & Co.
Dow Jones · 03/03 12:28
Akero Therapeutics: Strong Financials and Promising Clinical Progress Justify Buy Rating
TipRanks · 03/03 11:45
Promising Developments and Strong Financial Position Support Buy Rating for Akero Therapeutics
TipRanks · 03/03 11:26
Akero Therapeutics price target raised to $75 from $72 at H.C. Wainwright
TipRanks · 03/03 11:16
More
About AKRO
More
Akero Therapeutics, Inc. is a clinical-stage company. The Company is developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, including metabolic dysfunction-associated steatohepatitis (MASH), a disease without any approved therapies. Efruxifermin (EFX), is its lead product candidate for MASH, which is being evaluated in the ongoing phase IIb SYMMETRY, phase III SYNCHRONY Histology, and phase III SYNCHRONY real-world studies. The phase III SYNCHRONY program builds on the results of two phase IIb clinical trials, the HARMONY study in patients with pre-cirrhotic MASH and the SYMMETRY study in patients with cirrhosis due to MASH. EFX is an analog of fibroblast growth factor 21 (FGF21), which is an endogenously expressed hormone that protects against cellular stress and regulates metabolism of lipids, carbohydrates, and proteins throughout the body. EFX is designed to offer convenient once-weekly dosing.
Recently
Symbol
Price
%Change

Webull offers Akero Therapeutics Inc stock information, including NASDAQ: AKRO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, AKRO stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading AKRO stock methods without spending real money on the virtual paper trading platform.